The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Voluntarily participate in this clinical study, understand the research procedures and be able to sign the informed consent form in writing;
Participants must be aged between 18 and 70 years old (inclusive) when signing the informed consent form, and both men and women are eligible;
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
Adequate organ function;
With active, known or suspected autoimmune disease of autoimmune disease;
Malignancies other than NSCLC within 5 years prior to randomization;
Has or suspected has a history of pneumonitis / interstitial lung disease or any serve lung diseases which will influence the examination of lung function;
Significant history of cardiovascular and cerebrovascular disease; Significant haemorrhagic disease;